All paths are open when it comes to the biotech company Rhovac's journey foward. That is, as long as the results of the ongoing phase IIb trial with its lead candidate, RV001, which is a RhoC-based cancer vaccine, look promising, CEO at Rhovac Anders Månsson tells MedWatch.
On Monday, the Danish biotech business, which is listed in Sweden, announced that it had retained the international investment bank Stifel Nicolaus Europe, and together had begun looking into transaction or partnership opportunities for RV001.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Stallergenes Greer enters partnership to develop device and app
Stallergenes Greer and Aptar Pharma will collaborate to develop a new connected device with a companion app for patients going through treatment with the allergy company's allergen immunotherapy.
Lundbeck chairman demands change: "We can't live with this"
Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.
Coloplast could win big on Polish reimbursement changes
The Polish Ministry of Health has increased the reimbursement amount for hydrophilic catheters, which Coloplast supplies. The Danish medtech company calls the new scheme a "breakthrough."
Several positive elements in Eli Lilly Q3 report, says analyst
.jpg)
An analyst at Sydbank thinks that Eli Lilly's third quarter report includes a number of positive elements, and emphasizes that this could also be good news for competitor Novo Nordisk.
Eli Lilly upgrades earnings per share guidance
On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.
Chemist for Late Stage Analytical Development (1-year temporary position) 
Senior Clinical Trial Manager 
Clinical Business Process Manager 
Senior Manager/Associate Director Regulatory Affairs 
CMC Product Support Manager 
Senior Manager Pharmaceutical Development and Manufacturing 
GxP QA Compliance Manager for Quality Assurance 
Jr. Software Developer, Cardiac Applications – Medical Devices, DK 
QA Specialist wanted 
Principal Statistician / Statistical Project Director 
Head of Engineering, Syntese 
Global Product Manager 
KLIFO is looking for a talented and committed Pharmacovigilance Associate based in Denmark 
Regulatory Science Specialist